The standard KLOW dosage is 3.2 mg (10 units) per injection: daily during the activation phase in weeks 14, 5x per week during the remodeling phase in weeks 58, and 2-3x per week during maintenance in weeks 912
However, these findings are not yet backed by large human trials
FDA Status Most peptides used therapeutically are obtained through FDA-registered compounding pharmacies
Derived from a protective protein found in gastric juice, BPC-157 has demonstrated remarkable healing properties across a broad range of tissues in preclinical studies, including tendons, ligaments, muscles, bone, and the gastrointestinal tract
Swelling and some residual discomfort can persist for several weeks after surgery
Active malignancy warrants avoidance as discussed above